Key Points
- Director Maggie Yuen sold 3,000 AtriCure shares on Nov. 21 at an average price of $35.72 for about $107,160, cutting her stake by 20.88% to 11,371 shares (≈$406,172).
- AtriCure beat quarterly estimates with ($0.01) EPS and $134.27M revenue (up 15.8% YoY), but reiterated FY2025 guidance of roughly -0.260 to -0.230 EPS.
- Analyst sentiment skews positive—ten Buys vs. one Sell—with a consensus price target of $52.22 (some firms targeting up to $54.00).
AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Maggie Yuen sold 3,000 shares of the company's stock in a transaction that occurred on Friday, November 21st. The stock was sold at an average price of $35.72, for a total value of $107,160.00. Following the sale, the director owned 11,371 shares in the company, valued at approximately $406,172.12. This represents a 20.88% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
AtriCure Stock Up 0.0%
ATRC traded up $0.02 during trading on Tuesday, reaching $37.76. 45,583 shares of the stock were exchanged, compared to its average volume of 549,701. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.83 and a current ratio of 3.94. The stock's 50 day moving average price is $35.07 and its two-hundred day moving average price is $34.16. AtriCure, Inc. has a twelve month low of $28.29 and a twelve month high of $43.11. The stock has a market cap of $1.88 billion, a P/E ratio of -61.89 and a beta of 1.56.
AtriCure (NASDAQ:ATRC - Get Free Report) last announced its quarterly earnings data on Wednesday, October 29th. The medical device company reported ($0.01) EPS for the quarter, beating analysts' consensus estimates of ($0.11) by $0.10. The company had revenue of $134.27 million during the quarter, compared to the consensus estimate of $131.25 million. AtriCure had a negative net margin of 5.55% and a negative return on equity of 2.56%. The company's quarterly revenue was up 15.8% on a year-over-year basis. During the same quarter last year, the firm posted ($0.17) EPS. AtriCure has set its FY 2025 guidance at -0.260--0.230 EPS. Equities analysts expect that AtriCure, Inc. will post -0.6 EPS for the current year.
Wall Street Analyst Weigh In
ATRC has been the topic of several research reports. Wall Street Zen upgraded shares of AtriCure from a "hold" rating to a "buy" rating in a report on Saturday, August 2nd. Needham & Company LLC boosted their price objective on shares of AtriCure from $44.00 to $45.00 and gave the company a "buy" rating in a report on Wednesday, July 30th. Citigroup restated a "market outperform" rating on shares of AtriCure in a research report on Thursday, October 30th. Weiss Ratings reiterated a "sell (d-)" rating on shares of AtriCure in a research report on Wednesday, October 8th. Finally, BTIG Research set a $54.00 price objective on AtriCure in a research note on Wednesday, July 30th. Ten investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, AtriCure has an average rating of "Moderate Buy" and a consensus price target of $52.22.
Read Our Latest Research Report on ATRC
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in ATRC. Aster Capital Management DIFC Ltd grew its holdings in AtriCure by 197.1% during the 3rd quarter. Aster Capital Management DIFC Ltd now owns 811 shares of the medical device company's stock worth $29,000 after acquiring an additional 538 shares during the last quarter. Geneos Wealth Management Inc. bought a new stake in shares of AtriCure in the 2nd quarter valued at $37,000. Farther Finance Advisors LLC lifted its position in shares of AtriCure by 1,818.6% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,132 shares of the medical device company's stock valued at $40,000 after acquiring an additional 1,073 shares during the period. First Horizon Corp acquired a new position in shares of AtriCure during the 3rd quarter valued at $42,000. Finally, US Bancorp DE boosted its stake in AtriCure by 98.1% during the first quarter. US Bancorp DE now owns 1,593 shares of the medical device company's stock worth $51,000 after acquiring an additional 789 shares in the last quarter. Institutional investors own 99.11% of the company's stock.
AtriCure Company Profile
(
Get Free Report)
AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
